Stryker Corporation logo

Stryker Corporation(SYK)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 16 days
PROFIT SINCE LAST BUY
+0.81% ▲
LAST CLOSE
$309.64
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SYK

11/13/2026: SYK (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Stryker Corporation is a prominent global medical technology company known for its diverse portfolio of orthopedic implants, surgical equipment, and neurotechnology. Its core strengths include a well-regarded robotic-assisted surgery platform, Mako, and a highly effective direct sales model that fosters strong hospital partnerships. While the company has historically delivered steady growth, investors should monitor risks related to its reliance on elective procedure volumes and the competitive landscape of the medical device sector. The stock may suit growth-oriented investors looking for exposure to healthcare innovation or dividend-focused investors valuing long-term distribution growth. Success will likely depend on the company's ability to maintain its pace of innovation and effectively integrate new strategic acquisitions.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitConsistent historical revenue growth and ongoing investment in high-tech medical fields appeal to growth-oriented portfolios.
Momentum investorStrong fit while signal remains positiveStryker often displays strong price trends, making it attractive when technical signals support an upturn.
Value investorMixed fitThe stock often trades at a premium multiple due to its quality and growth, which may challenge strictly value-based investors.
Dividend investorStrong fitA history of reliable, growing dividends makes it a solid candidate for dividend growth strategies.
Low-risk investorMedium fitWhile established and stable, the medical device sector carries specific regulatory and market risks that investors must consider.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumThe stock can experience fluctuations based on sector-wide sentiments or elective volume data.
Valuation riskMedium / highThe premium valuation relative to the broader market reflects high expectations for continued innovation.
Competition risk (Medtech incumbents)MediumIntense rivalry from large, well-capitalized competitors can impact pricing power.
Business qualityStrongStryker's high margins and strong market presence indicate a high-quality business model.
Dividend incomeMediumDividends are reliable but yields are generally lower than high-yield income investments.
Execution riskMediumThe company's strategy relies heavily on the successful integration of frequent acquisitions.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 117.88B USD
Price to earnings Ratio 32.98
1Y Target Price 339.37
Price to earnings Ratio 32.98
1Y Target Price 339.37
Volume (30-day avg) 3.0M shares
Beta 0.77
52 Weeks Range 266.16 - 386.02
Updated Date 11/14/2026
52 Weeks Range 266.16 - 386.02
Updated Date 11/14/2026
Dividends yield (FY) 1.13%
Basic EPS (TTM) 9.39

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -13.42%
Avg. Invested days 39
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SYK receives a 4-star rating, supported by solid unit economics, solid company fundamentals, solid quantitative characteristics, and strong analyst coverage. The rating is constrained by weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
SYK has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and strong ownership. In FY2025 versus FY2024, moderate earnings growth (+8.5%) supports the fundamentals score.

Financial Health Rating

★★★★★
SYK's financial health is supported by strong cash strength, including free-cash-flow generation of $4.3B (17.1% of revenue). Profitability is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is SYK's strongest growth driver at +22.8% FY2025 versus FY2024 (solid, 4 stars). Revenue growth (+11.2%, solid) and earnings growth (+8.5%, moderate) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 82.1% and approximately 90.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 5.41% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 7.20%
Vanguard Capital Management, LLC 5.92%
JPMorgan Chase & Co 4.53%
State Street Corp 4.08%
Greenleaf Trust 4.00%

Unit Economics (Per $1K Revenue)

★★★★★
SYK generates approximately $640 of gross profit, $195 of operating income, and $171 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Solid margins and strong cash conversion support the rating, although capital efficiency remains moderate.

Economic Dimensions

★★★★★
Effective Tax Rate: 28.09%

Quantitative Style Profile

★★★★★
SYK has a high-quality, large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltLow VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
MedSurgSurgical instruments, robotics, and hospital beds.The largest segment, providing essential equipment for surgical environments.
OrthopaedicsHip, knee, and trauma implants.A core business segment tied to orthopedic surgical procedures.
Neurotechnology and SpineBrain and spine surgical tools.High-growth segment focused on specialized neurovascular and spinal needs.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-10-29
When After Market
Estimate 3.56
Actual 3.52

Profitability

Profit Margin 13.78%
Operating Margin (TTM) 23.97%

Management Effectiveness

Return on Assets (TTM) 8.36%
Return on Equity (TTM) 16.02%

Valuation

Trailing PE 32.98
Forward PE 19.27
Enterprise Value 130.58B
Price to Sales(TTM) 4.48
Enterprise Value 130.58B
Price to Sales(TTM) 4.48
Enterprise Value to Revenue 4.97
Enterprise Value to EBITDA 18.9
Shares Outstanding 380.69M
Shares Floating 345.81M
Shares Outstanding 380.69M
Shares Floating 345.81M
Percent Insiders 5.41
Percent Institutions 82.1

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.